Date: 2015-10-14
Type of information: Nomination
Compound:
Company: Bind Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 14, 2015, Bind Therapeutics, announced the appointment of Arthur Tzianabos, Ph.D., president and chief scientific officer of OvaScience, Inc., to the Company's board of directors. Dr. Tzianabos currently serves as president and chief scientific officer of OvaScience, a global fertility company dedicated to improving treatment options for women around the world. Dr. Tzianabos has more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joined OvaScience from Shire plc, where he served as senior vice president and head, Research and Nonclinical Early Development. Prior to Shire, Dr. Tzianabos was an associate professor of medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. During his time at Harvard, Dr. Tzianabos served as a consultant to several biotechnology and pharmaceutical companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters, and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.
Financial terms:
Latest news:
